India's medtech FDI fell in first 9 months of 2017, data show | FDA, EMA fast-track review of Novartis' blood cancer drug | Norgine's bowel cleansing drug gains marketing approval in 5 European countries
January 18, 2018
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
SIGN UP ⋅   FORWARD
Top Story
India's medtech FDI fell in first 9 months of 2017, data show
Data from India's Department of Industrial Policy and Promotion showed the medtech sector saw a drop in foreign direct investment during the first nine months of last year to $173 million, compared with $416.7 million in the same period last year. The decrease was attributed to the government's order to cap prices of certain medical devices, as well as to changes in the country's regulatory environment.
PharmaBiz (India) (1/15) 
LinkedIn Twitter Facebook Google+ Email
7 Essentials of Making Patient Videos
No emotion. No results. To harness the impact, reach, and results of emotion-eliciting health video you need a highly specialized team. Free white paper from our 15 years as specialists and pioneers in patient health video.
ADVERTISEMENT
Europe
FDA, EMA fast-track review of Novartis' blood cancer drug
The FDA granted priority review status to Novartis' Kymriah to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma. The drug also received an accelerated assessment from the European Medicines Agency for treating acute lymphoblastic leukemia in children and young adults.
Reuters (1/17) 
LinkedIn Twitter Facebook Google+ Email
Norgine's bowel cleansing drug gains marketing approval in 5 European countries
Norgine's bowel cleanser Plenvu gained marketing approval from regulatory authorities in Austria, Ireland, France, Italy and Portugal, and the company expects to launch the drug in those countries this year. The approval, which was supported by data from a late-stage trial, mean Plenvu is now approved in 10 European countries, plus Iceland and Australia.
PharmaBiz (India) (1/16) 
LinkedIn Twitter Facebook Google+ Email
EU OKs Shire's long-acting hemophilia A therapy
Shire's Adynovi, or rurioctocog alfa pegol, was approved by the European Commission as an on-demand and prophylactic treatment for patients at least 12 years old who have hemophilia A. The drug was modified to last longer in the blood, requiring less frequent injections -- from daily to just twice weekly.
PMLive (U.K.) (1/15) 
LinkedIn Twitter Facebook Google+ Email
Asia Pacific
OTC codeine sales banned in Australia
Over-the-counter sales of codeine will be banned in Australia effective Feb. 1, and products containing the drug must be obtained only through prescription after that date. The move is aimed at reducing opioid addiction, poisoning, tolerance and dependence.
In-Pharma Technologist (1/15) 
LinkedIn Twitter Facebook Google+ Email
Docetaxel vials recalled by Dr. Reddy's
Indian drugmaker Dr. Reddy's Laboratories recalled one lot of 1,051 vials of cancer drug Docetaxel for injection because of a defect in the vial's seal, according to the company.
The Economic Times (India)/Press Trust of India (1/17) 
LinkedIn Twitter Facebook Google+ Email
Singapore approves Histoindex's digital pathology imaging system
Singapore's Health Sciences Authority gave Histoindex a Class A license for its stain-free Laennec digital pathology imaging system, which is intended to facilitate clinical diagnosis of chronic liver diseases, including liver fibrosis. The technology enables tissue scanning and generation of digital images showing affected cells and collagen fibers using a novel Second Harmonics Generation and Two-Photon Excitation technology.
BioSpectrum Asia (1/15) 
LinkedIn Twitter Facebook Google+ Email
North America
FDA, DOD initiate accelerated review program for medical products, devices
FDA, DOD initiate accelerated review program for medical products, devices
(Scott Olson/Getty Images)
A new review program will be launched jointly by the FDA and the Department of Defense to expedite safety and efficacy review of medical products and devices judged to be essential for lifesaving treatments of US military personnel, with high-priority products for review to include cold-stored platelets, cryopreserved platelets and freeze-dried plasma. At least one workshop will be held by the agency and the department this year to inform FDA guidance on determining "unmet medical needs for battlefield settings," according to an initial blueprint for the initiative.
Seeking Alpha (free registration) (1/16),  MedPage Today (free registration) (1/16) 
LinkedIn Twitter Facebook Google+ Email
 
Global
Report predicts growth for global spinal implants, devices market
A Credence Research report predicts the worldwide market for spinal implants and surgical devices will see a 6.1% compound annual growth rate through 2025, hitting $21 billion. The market is led by North America in revenue share, although the Asia-Pacific region has seen an increase in product demand.
Becker's Spine Review (1/16) 
LinkedIn Twitter Facebook Google+ Email
DIA News
New year -- new Global Forum with a fresh new look!
Use any device to comfortably access our always-original content on a brand-new digital platform that connects you to expert insights, podcast interviews, legislative reports, guidances and other important developments. Take a look!
LinkedIn Twitter Facebook Google+ Email
Educational resources for the life sciences professional
LinkedIn Twitter Facebook Google+ Email
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
  
  
It is impossible to live without failing at something, unless you live so cautiously that you might as well not have lived at all -- in which case, you fail by default.
J.K. Rowling,
writer
LinkedIn Twitter Facebook Google+ Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information